---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000482"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:39.434805+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Anavex withdraws EU marketing application for blarcamesine for early Alzheimer's after CHMP negative feedback

## Summary
- Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.
- Decision follows CHMP indication it would not issue a positive opinion at this time.
- Company will gather additional data and conduct further analyses to address CHMP concerns.
- Anavex had submitted application after EMA SME Office encouragement in October 2023.
- CEO affirms commitment to advancing oral therapies for early Alzheimer's and continuing regulatory engagement.

## SEC filing metadata
- accession: 0001731122-26-000482
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000482/0001731122-26-000482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000482/e7494_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000482
- JSON: https://secwatch.observer/filing/0001731122-26-000482.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.